Spain's leading drug distributor Cofares has decided to set up its own company for the manufacture and marketing of non-prescription medicines. The company has invested 5.0 million euros ($7.3 million) in the new enterprise, to be called Farline. Sales in the first 12 months of operation are expected to reach 6.0 million euros.
Director general Jose Antonio Lopez Arias said a market share of 3% was feasible within the first three years of operation. The company controls 20% of the Spanish mainstream drug distribution business.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze